Evidence map›Paper›PMID 41313442›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2026

Pharmacokinetics of a single-pill combination of rosuvastatin and ezetimibe (2.5 mg/10 mg) in healthy Chinese subjects: an open-label, two-period, phase I study.

Ying Wang, Jiaxiang Ding, Dongmei Cheng, Yuzhou Ding, Tonghao Zhang, Wang Hu, Xiaoni Wang, Xu Zhu, Yunqiu Xie, Huan Zhou

Abstract readClinical Trial, Phase I
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ying Wang *Clinical Research Hospital, the First Affiliated Hospital of Anhui Medical University, No. 218 Jixi Road, Shushan District, Anhui Province, Hefei, 233004, China.
Jiaxiang Ding *Clinical Research Hospital, the First Affiliated Hospital of Anhui Medical University, No. 218 Jixi Road, Shushan District, Anhui Province, Hefei, 233004, China.
Dongmei ChengClinical Research Hospital, the First Affiliated Hospital of Anhui Medical University, No. 218 Jixi Road, Shushan District, Anhui Province, Hefei, 233004, China.
Yuzhou DingClinical Trial Research Center, The First Affiliated Hospital of Bengbu Medical University, Bengbu, 230031, China.
Tonghao ZhangClinical Trial Research Center, The First Affiliated Hospital of Bengbu Medical University, Bengbu, 230031, China.
Wang HuClinical Trial Research Center, The First Affiliated Hospital of Bengbu Medical University, Bengbu, 230031, China.
Xiaoni WangClinical Trial Research Center, The First Affiliated Hospital of Bengbu Medical University, Bengbu, 230031, China.
Xu ZhuClinical Trial Research Center, The First Affiliated Hospital of Bengbu Medical University, Bengbu, 230031, China.
Yunqiu XieClinical Research Hospital, the First Affiliated Hospital of Anhui Medical University, No. 218 Jixi Road, Shushan District, Anhui Province, Hefei, 233004, China. yunqiuxie@bbmc.edu.cn.
Huan ZhouClinical Research Hospital, the First Affiliated Hospital of Anhui Medical University, No. 218 Jixi Road, Shushan District, Anhui Province, Hefei, 233004, China. zhouhuan@fy.ahmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The single-pill combination of rosuvastatin and ezetimibe effectively reduces low-density lipoprotein cholesterol (LDL-C), while the pharmacokinetics of the single-pill combination of rosuvastatin and ezetimibe at a dosage of 2.5 mg/10 mg are seldom reported. This study aimed to evaluate the pharmacokinetics of a single-pill combination of rosuvastatin and ezetimibe (2.5 mg/10 mg) in healthy Chinese adult subjects. In this open-label, two-period, phase I study, 16 healthy subjects were enrolled and were administered a single-pill combination of rosuvastatin and ezetimibe (2.5 mg/10 mg) on day (D) 1 (single-dose period) and D14 to D23 once daily (multiple-dose period) under fasting conditions. The plasma concentrations of free ezetimibe, total ezetimibe, and rosuvastatin were determined. The pharmacokinetic parameters, including peak plasma concentration (C

Indexed as

Anticholesteremic AgentsAzetidinesEzetimibeHydroxymethylglutaryl-CoA Reductase InhibitorsRosuvastatin CalciumAdultArea Under CurveAsian PeopleDrug CombinationsEast Asian PeopleFemaleHealthy VolunteersHumansMaleYoung AdultAnticholesteremic AgentsAzetidinesDrug CombinationsEzetimibeHydroxymethylglutaryl-CoA Reductase InhibitorsRosuvastatin CalciumDyslipidemiaEzetimibePharmacokineticsRosuvastatinSingle-pill combination

Identifiers

PMID41313442

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.